Skip to content

Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement

Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04863456
Enrollment
90
Registered
2021-04-28
Start date
2021-05-01
Completion date
2024-12-31
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Adenoma

Keywords

pituitary adenoma, treatment strategy, Hypothalamus

Brief summary

Prospective and randomized evaluate efficiency and safety of different treatment strategies for hypothalamus-invading pituitary adenomas (HIPA)

Detailed description

There are various treatment strategies for hypothalamus-invading pituitary adenomas (HIPA), such as total resection (TR), subtotal resection with radiosurgery (STR+RS), etc. However,the optimal treatment of HIPA is still controversial. In this study, we want to evaluate the efficiency and safety of different treatment strategies in adults with HIPA.

Interventions

Total resection of HIPA in a single surgery

HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date

PROCEDURESubtotal resection followed by stereotactic radiation therapy

HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Suspected symptomatic or progressively growing pituitary adenoma with Hypothalamic Involvement * Informed consent

Exclusion criteria

* No follow-up possible * Emergency surgery without informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change of QoL (Quality of Life, EQ-5D) for the first surgerybaseline (before the first surgery), 2 years after the first surgeryEQ-5D will be evaluated before the first surgery and after the first surgery in 2 years
Change of QoL (Quality of Life, EQ-5D) for the second interventionbaseline (before the second intervention), 3 months after the second interventionEQ-5D will be evaluated before the second intervention and after the second intervention in 3 months

Secondary

MeasureTime frameDescription
Change of Visual Acuity statuebaseline (before the first surgery), 2 years after the first surgeryVisual Acuity statue will be evaluated using Snellen's chart before the first surgery and after the first surgery in 2 years
Change of Visual Field statuebaseline (before the first surgery), 2 years after the first surgeryVisual Field statue will be evaluated using a Humphrey visual field analyser before the first surgery and after the first surgery in 2 years
Change of Hormone Replacement Therapybaseline (before the first surgery), 2 years after the first surgeryWhether the Hormone Replacement Therapy was used (Yes or No) before the first surgery and after the first surgery in 2 years
Extent of resectionbaseline (before the first surgery), 2 years after the first surgeryVolumetric analysis of tumor volume before the first surgery, intraoperatively and 3 months and 2 years after the first surgery will be performed. In addition, Tumor volume will be evaluated before the second intervention and intraoperatively. Gross total resection is defined as no tumor present in gadolinium enhanced T1 sequences.

Contacts

Primary ContactTao Huang, PhD, MD
neuroht@hust.edu.cn027-85350819

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026